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Abstract: The phospholipids (PLs) of large yellow croaker (Pseudosciaena crocea, P. crocea) roe contain
a high level of polyunsaturated fatty acids, especially docosahexaenoic acid (DHA), which can
lower blood lipid levels. In previous research, PLs of P. crocea roe were found able to regulate the
accumulation of triglycerides. However, none of these involve the function of DHA-containing
phosphatidylcholine (DHA-PC), which is the main component of PLs derived from P. crocea roe.
The function by which DHA-PC from P. crocea roe exerts its effects has not yet been clarified. Herein,
we used purified DHA-PC and oleic acid (OA) induced HepG2 cells to establish a high-fat model,
and the cell activity and intracellular lipid levels were then measured. The mRNA and protein
expression of Fatty Acid Synthase (FAS), Carnitine Palmitoyl Transferase 1A (CPT1A) and Peroxisome
Proliferator-Activated Receptor α (PPARα) in HepG2 cells were detected via RT-qPCR and western
blot as well. It was found that DHA-PC can significantly regulate triglyceride accumulation in HepG2
cells, the effect of which was related to the activation of PPARα receptor activity, upregulation of
CPT1A, and downregulation of FAS expression. These results can improve the understanding of
the biofunction of hyperlipidemia mediated by DHA-PC from P. crocea roe, as well as provide a
theoretical basis for the utilization of DHA-PC from P. crocea roe as a functional food additive.
Keywords: large yellow croaker roe; DHA-PC; hyperlipidemia; regulatory effect; mechanism
1. Introduction
Fish roe has a high percentage of phosphatidylcholine (PC) [1,2], which has been shown to be
effective for the improvement of learning ability and the reduction of plasma lipids [3,4]. Fish roe has
also been reported to contain large amounts of n-3 polyunsaturated fatty acids (n-3 PUFAs), mainly
eico-sapentaenoic acid (EPA) and docosahexaenoic acid (DHA), which have been determined to be able
to prevent coronary heart disease, cardiovascular diseases [5], inflammation [6], cancer [7] and so on.
However, the applicability of bioactive compounds can be limited by their low stability, which leads to
their consequent degradation and loss of activity. Liposomes have attracted wide attention due to their
high bioavailability, biodegradability, safety, and amphiphilicity. They have considerable potential for
application in the food industry to encapsulate and protect nutraceuticals and other bioactive agents,
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such as vitamins, polyphenols, enzymes, carotenoids, and fatty acids [8–11]. At present, liposomes
have been widely used as drug carriers [12–15]. Although liposomes have been used for medical and
cosmetic purposes, their applications in food systems are relatively new [16].
Recently, these PLs containing polyunsaturated fatty acids (PUFAs) have received much attention
because of their health benefits. Some reports have shown that unsaturated PLs provide numerous
advantages in the prevention and treatment of cardiovascular disease, autoimmune disorders and
neurological disease [17,18]. Marine PLs are much high in PUFAs [19]. Tsoupras et al. reported that
several marine sources contain bioactive PLs, which has strong antithrombotic and atherosclerotic
cardioprotective activities [20]. Nasopoulou et al. found that fish PLs retard atherosclerosis by
upregulating platelet-activating factor (PAF) catabolism and down-regulating PAF biosynthesis in
rabbits [21]. Most n-3 PUFAs from fish roe are present in the phospholipid (PL) form, of which PC
is the predominant lipid class [1,22]. PLs containing n-3 PUFAs possess stronger bioactivities than
the n-3 PUFAs. Rossmeisl et al. found that PLs rich in n-3 PUFAs can prevent non-alcoholic fatty
liver disease [23]. PC, DHA, and EPA have many unique biological activities based on their own
functional properties. Some studies have reported that their combination could have more powerful
effects on adjusting liver and blood plasma lipid levels [24,25]. There is evidence that PLs combined
with n-3 PUFAs (such as EPA and DHA) are more efficiently incorporated into tissue membranes [19].
Previous reports have also demonstrated that fish roe contained a high amount of DHA-containing
phospholipid (DHA-PL) [26,27].
P. crocea is known among consumers for its delicious taste and high nutritional value [28,29].
Especially in the southern part of China, people are accustomed to eating P. crocea and its roe, and the
utilization of P. crocea roe has attracted the attention of many researchers [30]. We have found that
P. crocea roe contained high levels of total lipids (19.6 ± 1.32%, w/w) and phospholipids (61.2 ± 1.22%
of the total lipid, w/w) [31]. Roe is a major byproduct of P. crocea processing and is a potential
source of DHA-PL, which have a high amount of DHA (31.0 ± 0.19% of the total phospholipids,
w/w) and EPA as well as high content of PC (61.06 ± 0.02% of the total phospholipids, w/w) and
Phosphatidylethanolamine (PE) [31]. Further study demonstrated that DHA-PL was able to prevent
fatty degeneration of liver tissues and reduce the risk of atherosclerosis [32,33]. However, there are few
reports on the effects of DHA-PC, and the mechanisms by which it acts have not yet been elucidated.
Because of the large size of the P. crocea roe, and in particular its PLs, has more potential to be
exploited. Furthermore, considering the high proportion of PCs in PLs from P. crocea roe, marine PCs
are worthy of further exploitation. In this study, we explored the effect of DHA-PC from P. crocea roe
on triglyceride accumulation in HepG2 cells, which was done for the first time by establishing the
high-fat cell model. We also used RT-qPCR and western blot to initially illuminate the mechanism by
which the DHA-PC exerts these effects. These results would enhance our understanding of the effect
of DHA-PC from P. crocea roe on triglyceride accumulation in HepG2 cells.
2. Results and Discussion
2.1. Characterization of DHA-PC Liposomes
The liposomes prepared by the film dispersion method in this experiment were milky white
suspensions. Liposomes were evenly distributed, showed a spherical shape, and the particles were
dispersed well without aggregation. The average particle size of the liposomes was 234.4 nm, and the
dispersion coefficient polydispersity index (PDI) was 0.209, indicating that the prepared liposomes
had a uniform particle size distribution.
2.2. Cytotoxicity Evaluation
To determine whether different concentrations of DHA-PC liposomes were toxic to HepG2 cell,
we used MTT calorimetry to evaluate the effect of sample concentration on cell viability. The results
(Figure 1A) showed that, when treated for 24 h, there was no significant change in the proliferation
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activity of HepG2 cells until the treated concentration of DHA-PC liposomes reached 200 µg/mL,
which produced an inhibition rate (IR) of 26%. With the prolongation of treatment time to 48 and
72 h, the inhibition effect enhanced. With the increase of the concentration of DHA-PC liposomes,
the inhibition effect increased. The cell viability was still more than 80% when the concentration of
DHA-PC liposomes was 50 µg/mL, indicating that DHA-PC liposomes was not toxic to the cells at the
concentration of 50 µg/mL. The results were in agreement with those of Hwang et al. [34].
On the basis of these findings, the release of cellular lactate dehydrogenase (LDH) was also
examined. The release of LDH from cells is an important indicator of cell membrane integrity, and hence
was used to evaluate the cytotoxicity of DHA-PC liposomes. The release rate of lactate dehydrogenase
(LDH) in HepG2 cells was expressed by optical density (OD) value. After treatment by 10, 20, 40,
and 50 µg/mL of DHA-PC liposome for 24 and 48 h, the LDH activity of cells changed, but the
differences were not significant. Compared with the control group, the content of LDH in the HepG2
cells treated with 50 µg/mL DHA-PC liposomes for 72 h was significantly higher than that of the
control group, with a significant difference (p < 0.01). At the concentration of 50 µg/mL, DHA-PC
liposomes showed a toxic effect on the cells (Figure 1B). Therefore, DHA-PC liposome concentrations
10, 25, and 40 µg/mL were selected for subsequent studies.
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Figure 1. Cytotoxicity evaluation after treated with docosahexaenoic acid-containing 
phosphatidylcholine (DHA-PC) liposomes. (A) HepG2 cells were exposed to various concentrations 
(25, 50, 100, 150, 200 μg/mL) of DHA-PC liposomes for 24, 48, 72 h, and the cell viability was 
determined by MTT tests. The DHA-PC liposomes were considered not toxic to cells when the cell 
viability was more than 80%. On the basis of (A), (B) HepG2 cells were exposed to various 
concentrations (10, 20, 40, 50 μg/mL) of DHA-PC liposomes for 24, 48, 72 h, and the release rate of 
lactate dehydrogenase (LDH) in HepG2 cells was expressed by the OD value. (A and B) The same 
volume of medium was added to the control (0 μg/mL) group. P-P plot was used to verify that the 
data met the normal distribution. ANOVA test was used for comparisons and Kolmogorov–Smirnov 
test was also used in Figure 1B. Compare with the control group，* P < 0.05，** P < 0.01. 
2.3. OA Induced HepG2 Cells to Establish a High-Fat Model in Vitro. 
When the concentration was lower than 0.75 mM, OA had no effect on cell vitality (more than 
80%). The cells began to die while the concentration of OA reached 1.0 mM (Figure 2A), indicating 
that OA had a certain inhibitory effect on cell viability at this concentration (P < 0.01). When the OA 
concentration was less than 0.75 mM, the triglyceride content increased as the OA concentration 
increased, reaching a maximum at 0.75 mM. As the OA concentration continued to increase to 1.0 
mM, the TG content decreased (Figure 2B), and there was a significant difference (P < 0.01) when 
compared with control group (without adding OA). The HepG2 human hepatoma cells were 
selected as the cell line for the study because they retain many functions of normal hepatocytes, 
including secretion and metabolism of lipoproteins. In addition, the accumulation of free fatty acids 
in HepG2 cells can reach a large load, similar to human fatty liver [35]. Therefore, HepG2 cells were 
a good choice for establishing a high-fat model in vitro [36,37]. OA is a common fatty acid found in 
Figure 1. Cytotoxicity evaluation after treated with docosahexaenoic acid-containing phosphatidylcholine
(DHA-PC) liposomes. (A) HepG2 cells were exposed to various concentrations (25, 50, 100, 150,
200 µg/mL) of DHA-PC liposomes for 24, 48, 72 h, and the cell viability was determined by MTT tests.
The DHA-PC liposomes were considered not toxic to cells when the cell viability was more than 80%.
On the basis of (A,B) HepG2 cells were exposed to various concentrations (10, 20, 40, 50 µg/mL) of
DHA-PC liposomes for 24, 48, 72 h, and the release rate of lactate dehydrogenase (LDH) in HepG2
cells was expressed by the OD value. (A,B) The same volume of medium was added to the control
(0 µg/mL) group. P-P plot was used to verify that the data met the normal distribution. ANOVA test
was used for comparisons and Kolmogorov–Smirnov test was also used in Figure 1B. Compare with
the control group, * p < 0.05, ** p < 0.01.
2.3. OA Induced HepG2 Cells to Establish a High-Fat Model in Vitro
When the concentration was lower than 0.75 mM, OA had no effect on cell vitality (more than
80%). The cells began to die while the concentration of reached 1.0 mM (Figure 2A), indicating
that OA had a certain inhibitory effect on cell viability at this concentration (p < 0.01). When the
OA concentration was less than 0.75 mM, the triglyceride content increased as the OA concentration
increased, reaching a maximum at 0.75 mM. As the OA concentration continued to increase to 1.0 mM,
the TG content decreased (Figure 2B), and there was a significant difference (p < 0.01) when compared
with control group (without adding OA). The HepG2 human hepatoma cells were selected as the cell
line for the study because they retain many functions of normal hepatocytes, including secretion and
metabolism of lipoproteins. In addition, the accumulation of free fatty acids in HepG2 cells can reach a
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large load, similar to human fatty liver [35]. Therefore, HepG2 cells were a good choice for establishing
a high-fat model in vitro [36,37]. OA is a common fatty acid found in human plasma and is the final
product of de novo synthesis of fatty acids. Excessive accumulation of OA can cause hepatic steatosis in
humans [38]. OA is more steatogenic but less apoptotic than other saturated fatty acids (i.e., palmitic
acid) in hepatocyte culture, indicating that OA has a protective effect on hepatocytes [39]. Chen et al.
have demonstrated that OA has great potential to combat liver lipid toxicity induced by saturated fatty
acids in hepatocytes and Nash rats [40].
There was no red lipid droplet deposition at the edge of HepG2 cells in the control group,
while significant red lipid droplets were observed in the b, c, d and e groups. As the concentration
of OA increased (0.2 to 0.75 mM), some lipid droplets became larger (Figure 2(Ca–d)). However,
when treated with 1.0 mM OA, the number of cells was remarkably reduced; some cells were irregular
in shape, and some motility was observed (Figure 2(Ce)). Therefore, when the concentration of OA
selected was 0.75 mM, HepG2 cells showed no obvious proliferation defect. The cells contained
a large number of lipid droplets, and the TG accumulation reached a high level (Figure 2(Cd)),
indicating that the high-fat model in vitro was successfully established, which was basically consistent
with previous reports [41,42]. However, there were differences in the concentration of OA used in
different experiments.
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Figure 2. OA induced HepG2 cells to establish a high-fat model in vitro. (A, B and C) HepG2 cells 
were incubated with OA (oleic acid) at different concentrations (0.2, 0.5, 0.75, 1.0 mM). The cell 
viability was measured by MTT assay (A) and the intracellular TG content was determined 
according to the kit instruction (B). The OA was considered not toxic to cells when the cell viability 
was more than 80% (A). (C) OA-induced steatosis in HepG2 cells were determined by Oil Red O 
staining. P-P plot was used to verify that the results had no normality, then Kolmogorov–Smirnov 
test was used for comparisons. a: control；b: 0.2 mM OA；c: 0.5 mM OA；d: 0.75 mM OA；e: 1.0 
mM OA. (A, B and C) The same volume of medium was added to the control (0 μg/mL) group. 
Compare with the control group, * P < 0.05，** P < 0.01. 
2.4. Effect of DHA-PC on the Accumulation of Triglyceride in HepG2 Cells Induced by OA. 
To quantitatively analyze the effect of DHA-PC on triglyceride (TG) deposition in HepG2 cells 
induced by OA, we determined the change of triglyceride content in the cells. The TG content of the 
i r . i ced ep 2 cells to establish a high-fat model in vitro. (A–C) HepG2 cells w re
incubated with OA (oleic acid) at different concentrations (0.2, 0.5, 0.75, 1.0 mM). The cell viability
w s measured by MTT assa (A) and the intracellular TG content w s determi ed according to the kit
instruction (B). The OA was c sidered not toxic to cells when the cell viability as more than 80% (A).
(C) OA-induced steatosis in HepG2 cells were determi ed by Oil Red O staining. P-P plot was us to
verify that the results had no normality, then Kolmogorov–Smi nov est was used for c mpar sons.
a: control; b: 0.2 mM OA; c: 0.5 mM OA; d: 0.75 ; e: 1.0 mM OA. (A–C) The same volume
of medium was d ed to the control (0 µg/mL) group. Compar with the control group, * p < 0.05,
** p < 0.01.
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2.4. Effect of DHA-PC on the Accumulation of Triglyceride in HepG2 Cells Induced by OA
To quantitatively analyze the effect of DHA-PC on triglyceride (TG) deposition in HepG2 cells
induced by OA, we determined the change of triglyceride content in the cells. The TG content of
the model group (MOD) was significantly higher than that of the control group (CON) (p < 0.01),
indicating successful modeling. Fenofibrate in the positive control group reduced intracellular lipid
content, which was significantly different from the model group (p < 0.01). The untreated group was
regulated by the function of the cell itself when compared with the model group, and the lipid content
of this group was shown to decrease (Figure 3A). DHA-PC groups had better lipid-lowering effects,
which decreased by 19.9%, 44.6%, and 28.6%, respectively when treated for 24 h.
Compared with 48 h, the lipid-lowering effect of DHA-PC was further improved after 72 h of
treatment. After adding 40 µg/mL DHA-PC for 72 h, the lipid content of intracellular lipids decreased
to 30.6% compared to the model group, and the lipid-lowering effect was better than that of the
fenofibrate group. Therefore, 40 µg/mL was selected as the DHA-PC concentration for subsequent
experiments. The results showed that prolonging the intervention time of DHA-PC could further
enhance the lipid-lowering effect.
To observe the morphological effects of DHA-PC on OA-induced adipose accumulation in HepG2
cells, HepG2 cells were cultured for 24, 48, and 72 h with different concentrations of DHA-PC,
stained with oil red O and observed under a microscope. The model group had clear cell edges
with obvious red lipid droplets surrounding the cells, indicating successful model induction. As the
concentration of DHA-PC increased, the red lipid droplets in HepG2 cells gradually decreased, the lipid
droplets decreased, and the color became lighter. At the same concentration, the intracellular lipid
droplets were further reduced with the extension of time (Figure 3B).
Tung et al. found that the supplementation comprising dietary fish oil with all-trans retinoic acid
decreased blood lipids and fat accumulation in mice [43]. The results from Wang et al. showed that
DHA-PC exhibited strong effects for improving the dysfunction of memory and cognition [44]. In our
study, DHA-PC effectively reduced the deposition of lipid droplets in HepG2 cells, and the effect
increased with the prolongation of intervention time. The lipid-lowering effect of DHA-PC group was
better than that of fenofibrate, indicating that DHA-PC has a significant hypolipidemic effect. Thus,
we propose that DHA-PC is a potential lipid-lowering drug.
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2.5. Effect of DHA-PC on the mRNA Expression of Lipid Metabolism-Related Genes in HepG2 Cells
The above results showed that different concentrations of DHA-PC liposomes could reduce the
accumulation of fat in HepG2 cell. However, the mechanism by which DHA-PC liposomes prevents
the accumulation of fat in HepG2 cells was still not clear. Therefore, at the level of gene transcription
level, we evaluated the effect of exposure to 40 µg/mL DHA-PC liposomes on the expression of FAS,
CPT1A and PPARα in HepG2 cells by RT-qPCR.
2.5.1. mRNA Expression of Lipid Metabolism-Related Genes (FAS) in HepG2 Cells
The expression of FAS mRNA in the model group increased compared with the control group,
and the difference was statistically significant (p < 0.01). Compared with the model group, the DHA-PC
liposomes effectively reduced the expression of FAS mRNA in HepG2 cells induced by OA (Figure 4A),
and the difference was statistically significant (p < 0.05). Among them, the effect of DHA-PC liposome
on the expression of FAS mRNA in HepG2 cells was the most significant after 72 h, which was
56.4% lower than that of model group under the same treatment time. The results showed that the
expression of FAS mRNA in HepG2 cells decreased with the prolongation of time, revealing a certain
time-dependent effect. FAS is a key enzyme in the synthesis of fatty acids [45]. It is a multifunctional
complex enzyme with multiple regulatory sites, effectively inhibiting the expression of FAS and the
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synthesis of fatty acids. It has been proven that the effect of n-3 PUFAs-containing PC (n-3-PC) on
reducing lipid accumulation may be related to enzyme activity (such as CPT) and, specifically, to the
reduction of fat synthase activity (such as FAS), which is related to the increase of fat metabolism [46].
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to the control group, and the model group was added only with the same volume of 0.75 mM OA. 
The mRNA expressions of FAS (A), CPT1A (B) and PPARα (C) in HepG2 cells were detected by 
RT-qPCR. Expression levels were normalized to that of GAPDH mRNA expression. P-P plot was 
used to verify whether the data met the normal distribution. ANOVA test was used for comparisons 
in Figure 4B and Figure 4C. Kolmogorov–Smirnov test was also used in Figure 4A. CON: control, 
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model group, which was found to be a significant difference (P < 0.01). CPT1A has a widespread 
distribution and is found in liver, pancreas, kidney, brain, blood and embryonic tissues [47,48]. Liu 
et al. also found that the lipid-lowering effect on HepG2 cells was mediated by the upregulation of 
CPT1 and FAS gene expression [49]. 
Figure 4. DHA-PC down-regulated he mRNA expression of FAS and up-regulated mRNA expressions
of CPT1A and PPARα in HepG2 cells. (A–C) OA-induced HepG2 cells were xposed to DHA-PC
liposomes of 40 µg/mL f r 24, 48, 72 h. The same volume of mediu was added to the control group,
and the model r was added only with the same volume of 0.75 mM OA. The mRNA expressions of
FAS (A), CPT1A (B) and PPARα (C) in HepG2 cells were detected by RT-qPCR. Expression levels were
normalized to that of GAPDH mRNA expression. P-P plot was used to verify whether the data met the
normal distribution. ANOVA test was used for comparisons in Figure 4B,C. Kolmogorov–Smirnov test
was also used in Figure 4A. CON: control, MOD: model. Compared with the control group, ** p < 0.01;
Compared with the model group, # p < 0.05, ## p < 0.01.
2.5.2. mRNA Expression of Lipid Metabolism-Related Genes (CPT1A) in HepG2 Cells
Compared with the c ntrol group, the expression of CPT1A mRNA in the model group increased
(Figure 4B), and the difference was statistically significant (p < 0.01). There was no significant difference
in the expression of CPT1A mRNA in the HepG2 cells after DHA-PC treatment for 24 and 48 h.
The expression of CPT1A mRNA in DHA-PC cells treated for 72 h was significantly higher than
that of the model group, producing an increase in expression of 1.5 times that of the model group,
which was found to be a significant difference (p < 0.01). CPT1A has a widespread distribution and is
found in liver, pancreas, kidney, brain, blood and embryonic tissues [47,48]. Liu et al. also found that
the lipid-lowering effect on HepG2 cells was mediated by the upregulation of CPT1 and FAS gene
expression [49].
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2.5.3. mRNA Expression of Lipid Metabolism-Related Genes (PPARα) in HepG2 Cells
Compared with the control group, the expression of PPARα mRNA in the model group increased
when the model groups were treated with DHA-PC for 24 and 48 h (Figure 4C). The difference was
statistically significant (p < 0.01). DHA-PC was added to another model group for 72 h; compared
with the control group, the expression of PPARα mRNA in the model group decreased, and there was
a significant difference (p < 0.01). Compared with the model group, the expression of PPARα mRNA
in the DHA-PC liposome group was significantly increased in HepG2 cells. Among these groups,
the effect on the expression of PPARα mRNA in HepG2 cells treated with DHA-PC for 48 h was the
most obvious; the expression of PPARα was 3.6 times greater than that of the model group in the same
period, and the difference was statistically significant (p < 0.01). PPARα is an important subtype of the
PPARs family [50]. It is a nuclear hormone receptor that regulates the expression of genes involved in
lipid metabolism and is expressed in many cell types, such as T lymphocytes, macrophages, liver and
kidney cells [51,52].
2.6. Effect of DHA-PC on the Expression of Lipid Metabolism-Related Proteins in HepG2 Cells
After 24, 48, and 72 h, FAS protein expression in the model group was higher than that in the
control group, and the expression of PPARα protein in the model group was lower than that in the
control group (Figure 5), with significant differences (p < 0.01). When the cells were treated for 24 h,
the expression of CPT1A protein in the model group was not significantly different from that in the
control group (Figure 5A). The trend of CPT1A protein expression in the model group was consistent
with that of FAS after 48 and 72 h, and the difference was statistically significant (p < 0.01). Compared
with the model group, DHA-PC had a downregulation effect on the protein expression of FAS, and the
difference was significant (p < 0.01) after 24 and 72 h. However, there was no significant difference
when the cells were treated for 48 h (Figure 5B). The expression of both CPT1A and PPARα protein
was upregulated after treatment of 24, 48 and 72 h, with a significant difference (p < 0.01).
It has been revealed that elevated FAS expression can increase the accumulation of TG in the body,
leading to obesity [53]. This study found that, compared with the model group, the DHA-PC liposome
group showed reduced expression of FAS mRNA and protein in HepG2 cells at different time points.
However, there was no significant difference in the expression of CPT1A mRNA in HepG2 cells treated
with DHA-PC liposomes for 24 and 48 h. The expression of CPT1A mRNA increased significantly
in the DHA-PC group when the treatment time was prolonged to 72 h. Therefore, the relationship
between CPT1A and fatty acid metabolism needs further confirmation. Moreover, we also found that
DHA-PC can increase the expression of PPARα mRNA and protein in HepG2 cells when compared
with the control. It has been reported that activation of PPARα receptor activity is effective in reducing
TG levels in hepatocytes [54–56]. However, we only identified a limited number of genes (FAS, CPT1A
and PPARα) involved in lipid metabolism in HepG2 cells. Thus, further studies should be performed
to confirm our findings.
The above results showed the regulatory effect of hyperlipidemia mediated by DHA-PC from
P. crocea roe may be related to the downregulation of FAS, upregulation of CPT1A and activation of
PPARα. These results laid a theoretical foundation for further study on the molecular mechanism by
which DHA-PC regulates lipid metabolism in HepG2 cells. More work is still needed to elucidate the
specific lipid metabolic pathways.
Mar. Drugs 2019, 17, 485 9 of 16
Mar. Drugs 2019, 17, x FOR PEER REVIEW 9 of 16 
 
CON MOD DHA-PC
0.00
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
**
##
##
FAS
CPT1A
PPARα
GAPDH
CON MOD DHA-PC ##
**
Re
lat
ive
 pr
ote
in 
lev
el
 FAS
 CPT1A
 PPARα
24h
(A)
CON MOD DHA-PC
0.0
0.2
0.4
0.6
##
**
**
##
FAS
CPT1A
PPARα
GAPDH
CON MOD DHA-PC
*
Re
lat
ive
 pr
ote
in 
lev
el
 FAS
 CPT1A
 PPARα
48h
(B)
 
CON MOD DHA-PC
0.00
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
###
* **
##
**
FAS
CPT1A
PPARα
GAPDH
CON MOD DHA-PC
Re
lat
ive
 pr
ote
in 
lev
el
 FAS
 CPT1A
 PPARα
72h
(C)
 
Figure 5. DHA-PC down-regulated the protein expression of FAS and up-regulated protein 
expressions of CPT1A and PPARα in HepG2 cells. OA-induced HepG2 cells were exposed to 
DHA-PC liposomes of 40 μg/mL for 24 (A), 48 (B), 72 h (C). (A, B, and C) The same volume of 
medium was added to the control group, and the model group was added only with the same 
volume of 0.75 mM OA. The protein expressions of FAS, CPT1A and PPARα and the gray value 
corresponding to each protein expression in HepG2 cells were detected by Western blot. Expression 
levels were normalized to that of GAPDH protein expression. P-P plot was used to verify that the 
data met the normal distribution. ANOVA test was used for comparisons. CON: control, MOD: 
model. Compared with the control group，* P < 0.05，** P < 0.01；Compared with the model group, 
# P < 0.05，## P < 0.01. 
3. Materials and Methods 
3.1. Chemicals and Reagents 
Reagents and medium were purchased from Sigma (St. Louis, MO, USA), unless otherwise 
noted. DMEM high sugar medium and fetal bovine serum were purchased from Gibco (Grand 
Island, NY, USA). Streptomycin solution, trypsin-EDTA digestive cocktail (0.25%), dimethyl 
sulfoxide (DMSO), 4% paraformaldehyde, Oil red O dye and cell lysis buffer were obtained from 
Solaibao Technology Co., LTD (Beijing, China). MTT kit and LDH kit were purchased from Keji 
Biotechnology Co., LTD (Nanjing, China). TG kit was purchased from Nanjing Jiancheng Biological 
Engineering LTD (Nanjing, China). The BCA protein quantitation kit was obtained from Jinfu Sai 
Biotechnology Co., LTD (Beijing, China). Cholesterol and chloroform were purchased from National 
drug chemical reagents Co., LTD (Shanghai, China). Agarose was purchased from Biowest 
(Barcelona, Spain). Trizol, SYBR Green PCR Mix and RT-qPCR kits were obtained from Invitrogen 
(Carlsbad, CA, USA). 
Figure 5. DHA-PC down-regulated the protein expression of FAS and up-regulated protein expressions
of CPT1A and PPARα in HepG2 cells. OA-induced HepG2 cells were exposed to DHA-PC liposomes
of 40 µg/mL for 24 (A), 48 (B), 72 h (C). (A–C) The same volume of medium was added to the control
group, and the model group was added only with the same volume of 0.75 mM OA. The protein
expressions of FAS, CPT1A and PPARα and the gray value corresponding to each protein expression
in HepG2 cells were detected by Western blot. Expression levels were normalized to that of GAPDH
protein expression. P-P plot was used to verify that the data met the normal distribution. ANOVA test
was used for comparisons. CON: control, MOD: model. Compared with the control group, * p < 0.05,
** p < 0.01; Compared with the model group, # p < 0.05, ## p < 0.01.
3. Materials and Methods
1. Chemicals and R agent
Reagents and medium were purchased from Sigma (St. Louis, MO, USA), unless otherwise
noted. DMEM high sugar medium and fetal bovine serum were purchased from Gibco (Grand Island,
NY, USA). Streptomycin solution, trypsin-EDTA digestive cocktail (0.25%), dimethyl s lfoxide (DMSO),
4% paraformaldehyde, Oil red O dye and cell lysis buffer were obtained from Solaibao Technology
Co., LTD (Beijing, China). MTT kit and LDH kit were purchased from Keji Biotechnology Co.,
LTD (Nanjing, China). TG kit w s purchased f om Nanjing Jiancheng Biological Engineering LTD
(Nanjing, China). The BCA protein quantitatio kit was obtaine from Jinfu Sai Biotechnology Co., LTD
(Beijing, China). Cholesterol and chloroform were purchased from National drug chemical reagents
Co., LTD (Shanghai, Chi a). Agarose was purchased from Biowest (Barcelona, Spain). Trizol, SYBR
Green PCR Mix and RT-qPCR kits were obtain d fr m Invitrogen (Carlsbad, CA, USA).
3.2. Preparation of DHA-PC Liposomes
The DHA-PC was isolated and purified fromP. crocea roe in our previous work [57]. Total cholesterol
(TC) and DHA-PC with a mass ratio of 1:1.5 were dissolved in a round bottom flask with a volume of
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500 mL with a small amount of chloroform, and rotary evaporation was carried out at a temperature
of 30 ◦C to obtain a dry phospholipid film. A certain amount of D-Hanks was added and mixed,
then processed on the ultrasound system. DHA-PC liposomes were obtained after 200 nm microporous
filter membrane filtration.
3.3. Characterization of DHA-PC Liposomes
The DHA-PC liposomes were prepared in suspension in double-distilled water. After 2 min,
the liposomes were dyed with 2% phosphotungstate for 1 min; then, the liposomes were dried naturally
and observed with a scanning electron microscope [58]. The prepared DHA-PC liposomes were placed
in a nanometer particle size analyzer to determine their particle size. Each sample was generated
in triplicate.
3.4. Cell Culture and Treatment
The HepG2 cells purchased from the Nanjing KGI Biotechnology Co., LTD (Nanjing, China) were
cultured in DMEM complete medium with high glucose and 10% (vol/vol) fetal bovine serum at 37 ◦C.
The incubator contained 5% CO2, and the humidity was 100%.
When the cells were over 80% confluent, it was necessary to carry out the passage of HepG2 cells.
1 mL 0.25% trypsin (containing 0.02% EDTA) was added to the bottle for digestion. The trypsin was
discarded when the cells shrank and became round. The digestion was terminated by adding DMEM
complete medium, and the cells were gently pipetted to separate them from the bottle wall. The cell
suspension was aspirated and dispensed into a culture flask to continue the culture. The cells with
good growth state were frozen, and the frozen cells were resuscitated and transferred to a culture flask
for routine culture prior to use in subsequent experiments.
3.5. Cytotoxicity Evaluation
3.5.1. Determination of HepG2 Cell Viability Affected by Different DHA-PC Liposome Concentrations
HepG2 cells were digested with 0.25% trypsin, and cell suspension with a concentration of
2 × 105 cells/mL was prepared in DMEM complete medium; then, the suspension was cultured in a
96-well culture plate at 100 µL/well for 24 h. In the control group, only culture medium was added,
and the experimental group was treated with DHA-PC liposomes at concentrations of 25, 50, 100,
150, and 200 µg/mL. Five replicate wells were set in each group, and the plate was placed in a cell
culture incubator (37 ◦C, 5% CO2) for 24, 48, and 72 h. Four hours before the termination, 20 µL MTT
solution was added to each well; then, the culture was continued for another 4 h. Subsequently, 150 µL
DMSO was added per well. An oscillator was used for 5–10 min to completely dissolve the blue-purple
crystals. The OD value at 490 nm was measured by the microplate reader, and the cell survival rate
was represented by T (sample group OD value)/ C (control group OD value).
3.5.2. Determination of Lactate Dehydrogenase
HepG2 cells were inoculated at a cell concentration of 1 × 105 cells/mL in 96-well plates at
100 µL/well. After culturing for 24 h, the culture solution was discarded. The same volume of medium
was added to the control group, and the experimental group was treated with DHA-PC liposomes
at concentrations of 10, 20, 40, and 50 µg/mL. Five replicate wells were set in each group, and the
plate was placed in a cell culture incubator (37 ◦C, 5% CO2) for 24, 48, and 72 h. After the treatment,
the cell culture supernatant was collected, and the release rate of LDH was detected according to the
instructions of the LDH detection kit.
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3.6. OA Induced HepG2 Cells to Establish a High-Fat Model in Vitro
MTT, TG, and Oil red O staining experiments were carried out on cells from the model cell line.
The optimum concentration of OA was selected according to the cell viability, TG content, and dyeing
effect [59].
3.6.1. Determination of HepG2 Cell Viability Induced by Different Concentrations of OA
HepG2 cells passaged to the fourth passage were inoculated at a cell concentration of
2 × 105 cells/mL in a 96-well plate at 100 µL/well. After the cells adhered to the wall, the culture
medium was discarded, and the control group and the model group were prepared. Five replicate
wells were set in each group. The control group was cultured in DMEM complete medium, and the
model group was cultured for 24 h with medium containing different concentrations of OA (0.2, 0.5,
0.75, and 1.0 mmol/L). The viability of the cells was measured by MTT assay as described in 3.5.1.
3.6.2. Determination of TG content in HepG2 Cells
After adding trypsin for digestion, the medium was added to terminate the digestion. The medium
was gently pipetted several times, and the cell suspension was collected. Next, the cell pellet was
collected after cells were centrifuged at 1000 rpm/min for 5–10 min. Then, the pellet was washed
twice with PBS, and the cells added with cell lysis buffer were lysed on ice for 30 min, which was
followed by centrifugation at 10,000 rpm/min for 10 min at 4 ◦C; then, the supernatant was collected.
The TG content was then determined according to the kit’s instructions, by the single reagent GPO-PAP
method according to Nanjing Jiancheng Biological Engineering LTD.
3.6.3. Oil Red O Staining of Intracellular Lipids
After treatment, 4% paraformaldehyde was added to cells for 15–30 min, and cells were washed
twice with PBS and dyed with 60% isopropanol for 1–2 min. Then, 1.5 mL of Oil Red O staining
solution was added to the culture plate, and the mixture was kept in the dark for 0.5–1 h. The dye
solution was carefully removed from the edge; the slide was rinsed twice with distilled water and
observed and imaged with an inverted microscope. Each sample was generated in quintuplicate.
3.7. Detection of mRNA Expression of HepG2 Cell-Related Genes by RT-qPCR
Total RNA was isolated from the HepG2 cells using TRIzol reagent. The purity of RNA was
calculated by the following formula: OD260 × diluent factor × 40. The extracted total RNA was used
as a template for reverse transcription of cDNA. Reverse transcription product cDNA was subjected
to RT-PCR amplification using the Access RT-PCR System. The following primers were used, and
the size of the amplicon is given in parentheses: FAS, forward-CGTCTGTTGCTAGATTATCGTCC
and reverse-CTGTGCAGTCCCTAGCTTT (186 bp); CPT1A, forward-TCCAGTTGGCTTATCGTGGTG
and reverse-TCCAGAGTCCGATTGATTTTTGC (98 bp); PPARα, forward-AAACAAATGCCAGTA
TTGTCGATT and reverse-CTTTCTCAGATCTTGGCATTCGTC (99 bp); GAPDH, forward-ACAGC
CTCAAGATCATCAGC and reverse-GGTCATGAGTCCTTCCACGAT (104 bp). The amplification
conditions, such as the number of amplification cycles, were determined according to a kinetic profile.
GAPDH was used as an internal control. Ten microliters of RT-qPCR product from each group of cells
was mixed with DNA Marker and was subjected to gel electrophoresis in 1.5% agarose, observed and
photographed. Gel-Pro software was used to analyze the grayscale ratio of electrophoresis bands.
All RT-qPCR reactions were normalized against GAPDH expression. Three replicate samples for
each test.
3.8. Detection of Protein Expression of HepG2 Cell-Related Genes by Western Blot
After treatment, HepG2 cells were washed 3 times with cold PBS and lysed with RIPA lysis buffer.
The assay was performed according to the instructions of the BCA kit, and the protein concentration
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was calculated according to the standard curve. The same amount of protein for each sample was
mixed with loading buffer, boiled for 5 min and quickly cooled prior to loading for SDS-PAGE. Proteins
were blotted onto nitrocellulose filter (NC) membranes, which were then blocked by 5% skimmed milk
formulated with TBST for 1.5 h at room temperature. The NC membranes were then incubated with
specific primary antibodies overnight at 4 ◦C, followed by washing 3 times with TBST for 15 min each
time. Subsequently, HRP-labeled secondary antibodies were incubated for 1.5 h at room temperature
and then washed 3 times with TBST for 15 min each time. Finally, the blots were visualized using an
enhanced assay kit, and the bands were quantified using image software. Three parallel samples for
each test.
3.9. Statistical Analysis
The experimental data were expressed as the mean ± standard error of the mean (SEM). All data
were subjected to analysis of variance using SPSS 13.0 software. The P-P plot was used to verify that
the data met the normal distribution before using one-way ANOVA for comparisons. The differences
among control, OA, fenofibrate and DHA-PC groups were analyzed by one-way ANOVA followed
by the Student’s t-test. If there were no normality in the results, then non-parametric comparison
(Kolmogorov–Smirnov test) was used instead. And p< 0.05 was considered to be statistically significant.
4. Conclusions
DHA-PC could significantly regulate the accumulation of triglyceride in HepG2 cells, which was
evidenced by the reduced level of intracellular triglycerides. We speculated that the biofunction
utilized by DHA-PC to lower blood lipids may be related to the activation of PPARα receptor activity,
upregulation of CPT1A, and downregulation of FAS expression. In this study, it was concluded that
DHA-PC can exert a positive effect on the regulation of hyperlipidemia by DHA-PC from P. crocea
roe, contributing to the development of DHA-PC of P. crocea roe as a functional food additive and the
improvement of human health. Further works are still necessary to illuminate the specific molecular
mechanism which DHA-PC from P. crocea roe exerts the hyperlipidemic modulatory effects.
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Abbreviations
PLs phospholipids
P. Crocea large yellow croaker
DHA docosahexaenoic acid
DHA-PC DHA-containing phosphatidylcholine
OA oleic acid
FAS fatty acid synthase
CPT1A carnitine palmitoyl transferase 1A
PPARα peroxisome proliferator-activated receptor α
PC phosphatidylcholine
n-3 PUFAs n-3 polyunsaturated fatty acids
EPA eico-sapentaenoic acid
PUFAs polyunsaturated fatty acids
PAF Platelet-activating factor
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PL phospholipid
DHA-PL DHA-containing phospholipids
PE phosphatidylethanolamine
PDI polydispersity index
IR inhibition rate
LDH lactate dehydrogenase
OD optical density
TG triglyceride
n-3-PC n-3 PUFAs-containing PC
TC total cholesterol
NC nitrocellulose filter
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